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Objective: To examine the relationship between longitudinal fluctuations in synovitis with change in pain and
cartilage in knee osteoarthritis.
Methods: Study subjects were patients 45 years of age and older with symptomatic knee osteoarthritis from
the Boston Osteoarthritis of the Knee Study. Baseline and follow-up assessments at 15 and 30 months
included knee magnetic resonance imaging (MRI), BMI and pain assessment (VAS) over the last week.
Synovitis was scored at 3 locations (infrapatellar fat pad, suprapatellar and intercondylar regions) using a
semiquantitative scale (0–3) at all 3 time points on MRI. Scores at each site were added to give a summary
synovitis score (0–9).
Results: We assessed 270 subjects whose mean (SD) age was 66.7 (9.2) years, BMI 31.5 (5.7) kg/m2; 42%
were female. There was no correlation of baseline synovitis with baseline pain score (r = 0.09, p = 0.17). The
change in summary synovitis score was correlated with the change in pain (r = 0.21, p = 0.0003). An increase
of one unit in summary synovitis score resulted in a 3.15-mm increase in VAS pain score (0–100 scale).
Effusion change was not associated with pain change. Of the 3 locations for synovitis, changes in the
infrapatellar fat pad were most strongly related to pain change. Despite cartilage loss occurring in over 50%
of knees, synovitis was not associated with cartilage loss in either tibiofemoral or patellofemoral
compartment.
Conclusions: Change in synovitis was correlated with change in knee pain, but not loss of cartilage. Treatment
of pain in knee osteoarthritis (OA) needs to consider treatment of synovitis.
T
he cause of pain in knee osteoarthritis remains elusive as
the primary site of pathology in OA, cartilage, has no pain
fibres.1 Many other structures around the knee such as the
periosteum, subchondral bone, the fat pad, capsule and,
inconsistently, the synovium have been shown to contain
nociceptive fibres.1 In addition, inflammation itself appears to
play a role in increasing input from peripheral nociceptors.2
Biopsies of patients with both early and late knee OA have
shown low-grade chronic synovitis with production of pro-
inflammatory cytokines.3 4
Magnetic resonance imaging (MRI) allows evaluation of
multiple structures within the knee, including synovium,
cartilage, menisci, bone marrow lesions and effusion. In
cross-sectional studies of MRI in knee osteoarthritis (OA),
bone-marrow lesions, periarticular lesions, knee effusions and
synovitis have been shown to be more often present in persons
with knee pain than in persons with a comparable amount of
radiographic knee osteoarthritis but without pain.5–8
Fernandez-Madrid et al demonstrated that synovial thickening
seen on non-contrast enhanced MRI in the infrapatellar region
of knees with OA showed low-grade synovial inflammation on
biopsy. This feature was present in 73% of knees with early OA.9
We have previously shown that this synovial thickening is
present in persons with knee pain and OA much more often
than in persons with OA but without pain.7 Among those with
pain, the presence of MRI synovial thickening identified those
with more severe pain. While this evidence suggests that
synovial thickening may affect pain, these data are cross-
sectional, making it impossible to evaluate the temporal
relation of pain with synovial thickening. More persuasive
evidence would emanate from a longitudinal study in which
fluctuations in synovial thickening could be tied to fluctuations
in the severity of knee pain. Herein, we provide such evidence.
Our aims were to study the association between baseline and
longitudinal changes in MRI-detected synovitis and changes in
knee pain, and also to study the association between baseline
and longitudinal changes in synovitis and cartilage loss in
patients with symptomatic knee OA.
PATIENTS AND METHODS
Study population
Patients were recruited to participate in a natural history study
of symptomatic knee OA, the Boston Osteoarthritis of the Knee
Study. The recruitment for this study has been described in
detail elsewhere.10 Briefly, patients were recruited from two
prospective studies, one in men and one in women, of quality of
life among veterans; from clinics at Boston Medical Center in
Boston, Massachusetts; and from advertisements in local
newspapers. Potential participants were asked two questions:
‘‘Do you have pain, aching, or stiffness in one or both knees on
most days?’’ and ‘‘Has a doctor ever told you that you have knee
arthritis?’’ For patients who answered yes to both questions, we
conducted a follow-up interview in which we asked about other
types of arthritis that could cause knee symptoms. If no other
forms of arthritis were identified, then the individual was
eligible for recruitment. A series of knee radiographs (PA,
lateral and skyline) were obtained for each patient to determine
whether radiographic OA was present. If patients had a definite
osteophyte on any view in the symptomatic knee, they were
eligible for the study. Because they had frequent knee
symptoms and radiographic OA, all patients met American
College of Rheumatology criteria for symptomatic knee OA.11
Abbreviations: MRI, magnetic resonance imaging; OA, osteoarthritis;
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The study included a baseline and follow-up examinations at
15 and 30 months. At baseline, patients who did not have
contraindications to MRIs had an MRI of the more sympto-
matic knee. MRIs of the same knee were also performed at
follow-up visits. At each visit, pain in the imaged knee over the
past week was assessed using a visual analogue scale (VAS, 0–
100), and subjects were weighed with shoes off on a balance-
beam scale. The Institutional Review Boards of Boston
University Medical Center and the Veterans Administration
Boston Health Care System approved the study.
MRI measurements
All MRIs were performed with a Signa 1.5T system (General
Electric, Milwaukee, WI) using a phased-array knee coil. A
positioning device was used to ensure uniformity among
patients. Coronal, sagittal and axial images were obtained.
Fat-suppressed spin-echo proton density and T2-weighted
images (repetition time, 2200 ms; echo time, 20/80 ms) with
a slice thickness of 3 mm, a 1-mm interslice gap, one excitation,
a field of view of 11–12 cm, and a matrix of 2566128 pixels
were obtained.
Cartilage morphology was assessed by a musculoskeletal
radiologist (AG) using a semiquantitative, multi-feature scoring
method (whole-organ magnetic resonance imaging score,
WORMS) for whole-organ evaluation of the knee that is
applicable to conventional MRI techniques.12 Intraclass correla-
tion coefficients of agreement among the readers for cartilage
readings ranged from 0.72 to 0.97.
Tibiofemoral cartilage on MRI was scored on all 5 plates
(central and posterior femur; anterior, central and posterior
tibia) in each of the medial and lateral tibiofemoral joints. The
anterior femur was not included in this analysis, as this is part
of the patellofemoral joint. Patellofemoral cartilage was scored
on 4 plates (medial and lateral patella, and medial and lateral
anterior femur). These were read using the fat-suppressed T2-
weighted FSE images on a 7-point scale: 0 = normal thickness
and signal; 1 = normal thickness but increased signal on T2-
weighted images; 2 = partial-thickness focal defect ,1 cm in
greatest width; 3 = multiple areas of partial-thickness (Grade
2) defects intermixed with areas of normal thickness, or a
Grade 2 defect wider than 1 cm but ,75% of the region;
4 = diffuse (>75% of the region) partial-thickness loss;
5 = multiple areas of full-thickness loss wider than 1 cm but
,75% of the region; 6 = diffuse (>75% of the region) full-
thickness loss.
In WORMS, grade 1 does not represent a morphological
abnormality but rather represents a change in signal in
cartilage of otherwise normal morphology. Grades 2 and 3
represent similar types of abnormality of the cartilage, focal
defects without overall thinning. Scores of 1 and 2 were
exceedingly unusual. Therefore, to create a consistent and
logical scale for evaluation of cartilage morphological change,
we collapsed the WORMS cartilage score to a 0–4 scale, where
the original WORMS scores of 0 and 1 were collapsed to 0, the
original scores of 2 and 3 were collapsed to 1, and the original
scores of 4, 5 and 6 were considered 2, 3 and 4, respectively, in
the new scale.13 The intraobserver agreement for reading of
cartilage morphology ranged from 0.65 to 0.78 (kappa). We
defined a lesion as occurring in either the medial or lateral
tibiofemoral compartment if it was present in the femur or tibia
of that compartment. While we conducted analyses using this
collapsed WORMS cartilage scale, analyses using the original
scale yielded the same results.
On the baseline and follow-up MRIs, effusion was scored 0–3
based on volume. Bone-marrow lesions were scored only on the
baseline MRIs using the WORMS scale also in which lesions are
scored according to their size (0–3) within quadrants of the
femur and tibia.
Synovial reading
Synovial thickening on MRI using sagittal T2-weighted and
proton-density sequences was scored separately at 3 locations
(infrapatellar fat pad, suprapatellar and intercondylar regions)
using a semiquantitative scale (0–3) at all 3 time points (fig 1).
Given the confirmation that these MRI findings connote
inflammation in the synovium, we shall label these findings
as synovitis.
One reader (CLH) read synovitis on MRI’s. For each subject,
MRIs were blinded to subject’s identity and read paired and in
sequential order. The intraobserver agreement (kappa) for
Figure 1 (A) T2-weighted MR image, sagittal view, with soft tissue density
and surrounding synovitis in intercondylar region. (B) T2-weighted MR
image, sagittal view, with synovitis (grade 2) in infrapatellar region.
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infrapatellar fat pad synovitis score was 0.63, intercondylar 0.49
and suprapatellar 0.20.
Validation of non-gadolinium synovitis scoring
To validate non-gadolinium scoring, 20 subjects with knee OA
at University of Leeds underwent MRI using a sagittal T2
weighted fat suppressed sequence and a gadolinium enhanced
T1 weighted fat-suppressed sequence. A trained reader scored
the infrapatellar fat pad for synovial thickening on a 0–3 scale
using just the T2 sequence without reference to other sequences
(as above). The same reader then scored the infrapatellar
synovitis using the same scoring system using just the
postgadolinium sagittal sequence again without reference to
other sequences. The films were blinded and presented to the
reader in random order for the 2 reads, which took place
1 week apart. Of the 20 knees, 13 showed contrast (gadoli-
nium) enhanced and non-contrast enhanced scores that were
identical (ranging from 0 to 3). As expected, in 6 knees, the
non-gadolinium images underestimated the amount of syno-
vial thickening seen on the contrast enhanced image. Only one
knee showed an over-reading of synovial thickening on the
non-contrast image (score of 2 vs 1).
Analysis
Synovitis scores at each location were added to give a summary
synovitis score at each time point (0–9). Changes in synovitis
score were calculated at each time point. In addition, an
analysis was carried out for synovitis scores at each individual
site.
To examine whether differences in VAS pain score can be
explained by differences in synovitis both cross-sectionally and
longitudinally, we applied the generalised estimating equation
to test this hypothesis with the following statistical model:
Yit = b0+b1Xi0+b2(Xit–Xi0).
where Yit is the pain score assessed at baseline, at 15 months
and at 30 months. Xi0 is the synovitis assessed at baseline, and
Xit is the corresponding measure of synovitis assessed at time t,
that is, baseline, 15 months and 30 months, respectively. The
coefficient b1 measures the cross-sectional association of the
synovitis at baseline and VAS pain score, and b2 measures the
effect of changes in synovitis on changes of VAS pain score.
The interpretation of the estimate from the model is the
expected change in pain over time (from baseline to follow-up
including both 15 and 30 months) per unit change in synovitis
score in the corresponding follow-up period for a given subject.
To examine whether cartilage loss can be explained by
baseline synovitis, we used cartilage loss in each compartment
(medial tibiofemoral, lateral tibiofemoral, and patellofemoral)
in 30-month follow-up for analyses unless unavailable, in
which case cartilage loss in 15 months was used. Cartilage loss
took whole number values from 0 (no loss) to 4 (maximum
loss) and was analysed as ordered categories using the
proportional odds logistic regression model. A generalised
estimating equations correction was applied to the regression
model to account for the association in the cartilage loss
outcome between regions within a joint. For change in pain and
cartilage loss, analyses were adjusted for baseline cartilage
scores, age, sex, BMI, effusion score (0–3) and bone-marrow
lesion score (using WORMS), and change in both bone-marrow
lesion score and effusion score. For cartilage loss, we adjusted
additionally for baseline WORMS based meniscal score.
A similar method was used to examine whether cartilage loss
can be explained by synovitis change. The change in synovitis in
a 30-month follow-up was used for analyses unless unavailable,
in which case the change of synovitis in 15 month follow-up
was used.
RESULTS
We assessed 270 subjects (158 male, 112 female) with at least
one follow-up MRI. Two hundred and thirty-three subjects
were followed for 30 months, and 37 subjects were followed for
15 months. Demographic details are recorded in table 1. The
mean age of the subjects was 66.7 years, BMI 31.5 kg/m2 and
VAS pain score 44.2 mm. Most knees had evidence of synovitis
at one of the 3 sites at baseline, and about 40% had a change in
knee synovitis over time (table 1). The presence of synovitis at
baseline was significantly correlated with the baseline
Kellgren–Lawrence radiological grade. The Spearman correla-
tion was 0.44, 0.32, 0.27 and 0.39 for the Kellgren–Lawrence
grade and summary synovitis, synovitis in infrapatellar fat pad,
intercondylar and suprapatellar regions, respectively.
There was no correlation of baseline synovitis with baseline
pain score (Pearson correlation coefficient r = 0.09, p = 0.17);
an increase in synovitis score at basleine was correlated with a
slightly higher baseline VAS pain score (adjusted estimate per
increase in one unit of synovitis 0.72, 95% CI; 21.15, 2.59).
However, there was a correlation of change of pain with change
of synovitis score (r = 0.21, p = 0.0003; adjusted estimate of
3.15 VAS score change (on 0–100 scale) per unit change in
Table 1 Characteristics of subjects
Total 270 subjects
Gender 158 (58.5%) males, 112 females
Age (mean) 66.7 (9.2) years
BMI (mean) 31.5 (5.7) kg/m2
Kellgren–Lawrence grade* (median, range) 3 (0 to 4)
Baseline pain (mean, SD) (0–100) 44.2 (25.2) mm
Change in pain (mean, SD) from baseline to follow-up 21.9 (25.5) mm
Baseline synovitis score 0–9
Baseline infrapatellar fat pad score, 0/1/2/3 (%) 21.5/40.0/33.9/4.6
Baseline intercondylar notch score, 0/1/2/3 (%) 31.5/52.3/15.0/1.2
Baseline suprapatellar notch score, 0/1/2/3 (%) 24.5/41.2/22.2/12.1
Change in synovitis score
Change in infrapatellar fat pad score, decrease/no change/increase (%) 15.2/63.1/21.7
Change in intercondylar notch score, decrease/no change/increase (%) 14.3/66.8/18.9
Change in suprapatellar notch score, decrease/no change/increase (%) 20.4/59.2/20.4
Baseline cartilage score in 14 plates (mean, SD) 16.1 (9.2)
Baseline summary bone-marrow lesion (mean, SD) 3.2 (3.1)
Baseline effusion score (mean, SD) 0.9 (0.8)
*Subjects with ‘‘Knee pain/OA’’, who had Kellgren–Lawrence grade 0 due to normal PA views, were defined as having radiographic OA due to definite osteophytes in
patello-femoral joint; pain was measured on a 100-mm visual analogue scale.
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synovitis score 95% CI; 1.04, 5.26. p = 0.003). However, the
change in effusion score over time was not associated with pain
change (adjusted estimate 1.19, 95% CI; 28.08, 10.46.
p = 0.80). Similar results were seen in both males and females.
Of the 3 locations for synovitis examined separately, none of
the baseline synovitis scores was associated with baseline pain
(table 2). However, for each site, the change in synovial score
was associated with pain change. This relation was strongest
for the change in synovitis in infrapatellar and intercondylar fat
pads in which there was a 5.7-mm and 4.9-mm increase in
pain, respectively, per unit increase in synovitis. The relation
between change in synovitis at the suprapatellar region and
change in pain was not significant.
Despite cartilage loss occurring in over 50% of knees from
baseline to follow-up, baseline synovitis score was not
associated with cartilage loss in the patellofemoral compart-
ment and only in those with higher grades of synovitis in the
tibiofemoral compartment (table 3). The change in synovitis
score was not associated with cartilage loss in medial or lateral
tibiofemoral compartments, but there was a trend towards
increased cartilage loss in the patellofemoral compartment in
those with worsening synovitis scores (table 3).
DISCUSSION
Our study demonstrates that the change in synovitis over time
was correlated modestly with changes in knee pain, but not at
all with loss of cartilage. The correlation was direct—an
increase in synovitis was associated with worsening pain and
a decrease with less severe pain. This effect on pain was
independent of changes in knee-joint effusion. We have
demonstrated for the first time that longitudinal changes in
synovitis reflect changes in pain in knee OA. We failed to find
any association of synovial inflammation with cartilage loss.
Our findings regarding synovitis and cartilage loss are in
keeping with previous cross-sectional findings of no association
between arthroscopic synovitis or degree of synovial thickening
on MRI and cartilage loss on MRI in a cross-sectional study.14
We found little association between the change in synovitis
score and cartilage loss, suggesting that the two processes,
synovitis and cartilage loss, are, for the most part, independent.
Synovial thickening in the infrapatellar region, detected on
non-contrast MRI imaging, like that used in this paper, has
been shown to represent low-grade synovial inflammation
when biopsied in knee OA.9 The synovial scoring we used was
based on a previous study that demonstrated a good correlation
between the MRI semiquantitative scores and MRI synovial
volume measurements, suggesting that semiquantitative syno-
vitis scores are valid and enable feasible evaluation of the
synovium in OA cohorts.15 Gadolinium-enhanced MRI remains
the gold standard for the assessment of synovitis on MRI.
Although, we did not use gadolinium in our study, we did
validate non-gadolinium scoring and found that non-contrast
images can provide a valid measure of synovitis, as demon-
strated by gold-standard gadolinium-enhanced MR images in
knee OA.
Intra-articular sources of pain in knee OA such as the
synovium have been suggested by other studies which have
demonstrated the analgesic properties of intra-articular instil-
lation of local anaesthetic,16 low-dose morphine17 and steroid.18–
20 Another recent study suggested that intra-articular anakinra
(interleukin-1 receptor antagonist) given to 7 patients with
knee OA resulted in an improvement in pain, which paralleled
improvements in MRI synovial scores.21 Also, NSAIDs appear to
have a superior effect over acetaminophen for treatment of
knee OA in several studies, and this could be related to their
anti-inflammatory properties.22 23 These studies, along with our
observation that changes in pain are associated with changes in
synovitis, suggest that treatment of synovitis may be a key
element in the management of pain in knee OA. A limitation of
our study was that we did not collect sufficiently detailed
information on the use of analgesics and NSAIDs to allow this
to be utilised in the analysis.
The relation we found of synovitis change with pain change
was significant but only modest. This weak correlation (r = .21)
may be because there are other causes of change in pain
intensity in persons with knee osteoarthritis but may also be
due to the crude scale for synovitis change we used and our
inability to score synovitis in all sites in which it occurs within
the knee. Further, we had difficulty identifying suprapatellar
synovitis on non-contrast images, and that accounts for the
Table 2 Change in pain as a function of change in synovitis at individual sites*
Baseline synovitis and baseline VAS pain Change of synovitis and change of VAS pain
Estimate 95% CI p value Estimate 95% CI p value
Infrapatellar fat pad 2.31 21.54, 6.16 0.24 4.89 0.42, 9.36 0.03
Intercondylar 2.26 22.92, 7.45 0.39 5.74 0.34, 11.14 0.04
Suprapatellar 20.07 23.97, 3.82 0.97 3.35 20.34, 7.05 0.08
*Analyses adjusted for age, sex, BMI, cartilage score at baseline, effusion score (0–3), bone-marrow lesion score (WORMS), change in bone-marrow lesion score and
change in effusion score.
Table 3 Risk of cartilage loss by synovitis (adjusted odds ratio, 95% CI)*
Odds ratio for loss of cartilage in
medial tibiofemoral compartment
Odds ratio for loss of cartilage in
lateral tibiofemoral compartment
Odds ratio for loss of cartilage in
patellofemoral compartment
Baseline summary synovitis score
Summary synovitis score (0–2) Referent Referent Referent
Summary synovitis score (3–4) 2.9 (1.3, 6.5) 0.9 (0.4, 2.2) 1.3 (0.5, 3.3)
Summary synovitis score (5–9) 1.5 (0.6, 4.1) 1.0 (0.3, 2.9) 0.9 (0.2, 3.9)
Change in synovitis score
Improvement in synovitis score Referent Referent Referent
Stable synovitis score 0.7 (0.3, 1.6) 0.6 (0.2, 1.7) 1.9 (0.6, 5.7)
Worsening synovitis score 0.6 (0.2, 1.3) 1.1 (0.5, 2.9) 2.5 (0.8, 7.5)
*Analyses adjusted for age, sex, BMI, cartilage score at baseline, effusion score (0–3), bone-marrow lesion score (WORMS), change in bone-marrow lesion score and
change in effusion score.
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poor reliability of readings at this site. It may also explain why
we found stronger relations of pain change with synovitis at
other knee sites. Even so, our findings suggest that synovitis is
likely to contribute to the fluctuations in pain experienced by
persons with symptomatic knee OA and needs confirmation.
In conclusion, in this longitudinal MRI study, we found that
a change in synovitis score was associated with changes in pain
score. We did not demonstrate any association between
synovitis or its change and cartilage loss. Our findings have
clear-cut implications for the treatment of painful osteoarthritis
of the knee, as they suggest that treatments targeted to
synovitis may improve pain.
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